Recent research have focused on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor stimulant therapies and dopamine signaling. While GLP stimulators are commonly employed for managing type 2 diabetes, their emerging effects on reinforcement circuits, specifically mediated by dopamine pathways,